WO2008015383A3 - Bmp-9 and bmp-10 and their use in breast and prostate cancer therapies - Google Patents
Bmp-9 and bmp-10 and their use in breast and prostate cancer therapies Download PDFInfo
- Publication number
- WO2008015383A3 WO2008015383A3 PCT/GB2007/002755 GB2007002755W WO2008015383A3 WO 2008015383 A3 WO2008015383 A3 WO 2008015383A3 GB 2007002755 W GB2007002755 W GB 2007002755W WO 2008015383 A3 WO2008015383 A3 WO 2008015383A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bmp
- breast
- prostate cancer
- cancer therapies
- therapies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to the role of BMP-9 and/or BMP-10 in the treatment of breast or prostate cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0615129.4 | 2006-07-29 | ||
GBGB0615129.4A GB0615129D0 (en) | 2006-07-29 | 2006-07-29 | Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2008015383A2 WO2008015383A2 (en) | 2008-02-07 |
WO2008015383A3 true WO2008015383A3 (en) | 2008-08-14 |
WO2008015383A8 WO2008015383A8 (en) | 2009-07-16 |
Family
ID=37006438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2007/002755 WO2008015383A2 (en) | 2006-07-29 | 2007-07-20 | Bmp-9 and bmp-10 and their use in breast and prostate cancer therapies |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0615129D0 (en) |
WO (1) | WO2008015383A2 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2561048T3 (en) | 2004-07-23 | 2016-02-24 | Acceleron Pharma Inc. | ActRII receptor polypeptides |
KR20160137665A (en) | 2005-11-23 | 2016-11-30 | 악셀레론 파마 인코포레이티드 | Activin-actrπa antagonists and uses for promoting bone growth |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
AU2008211007B2 (en) | 2007-02-01 | 2013-09-19 | Acceleron Pharma Inc. | Activin-ActRIIa antagonists and uses for treating or preventing breast cancer |
TW202021980A (en) | 2007-02-02 | 2020-06-16 | 美商艾瑟勒朗法瑪公司 | Variants derived from actriib and uses therefor |
CA3039330C (en) | 2007-02-09 | 2021-11-09 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for promoting bone growth in cancer patients |
CN107412734A (en) | 2007-09-18 | 2017-12-01 | 阿塞勒隆制药公司 | Activin A CTRIIA antagonists and the purposes for reducing or suppressing FSH secretions |
WO2009084739A1 (en) * | 2007-12-28 | 2009-07-09 | Kyowa Hakko Kirin Co., Ltd. | Method and pharmaceutical composition for treatment of cancer using bmp10 protein, |
WO2009084738A1 (en) * | 2007-12-28 | 2009-07-09 | Kyowa Hakko Kirin Co., Ltd. | Method and pharmaceutical composition for treatment of cancer using bmp9 protein |
JP5922928B2 (en) | 2008-08-14 | 2016-05-24 | アクセルロン ファーマ, インコーポレイテッド | Use of GDF traps to increase red blood cell levels |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
EP2387412A4 (en) | 2009-01-13 | 2013-04-03 | Acceleron Pharma Inc | Methods for increasing adiponectin |
EP2440576A4 (en) | 2009-06-08 | 2013-11-20 | Acceleron Pharma Inc | Methods for increasing thermogenic adipocytes |
AU2010263182B2 (en) | 2009-06-12 | 2016-05-12 | Acceleron Pharma Inc. | Truncated ActRIIB-Fc fusion proteins |
CA2781152A1 (en) | 2009-11-17 | 2011-05-26 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
CA2817008A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma Inc. | Actriia binding agents and uses thereof |
US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
ES2884095T3 (en) | 2012-11-02 | 2021-12-10 | Celgene Corp | Activin-actrii antagonists and uses for treating bone and other disorders |
BR122023023170A2 (en) | 2014-06-13 | 2024-02-20 | Acceleron Pharma Inc. | USE OF AN ACTRII ANTAGONIST IN THE TREATMENT OR PREVENTION OF SKIN ULCERS ASSOCIATED WITH BETA-THALASSEMIA |
MA41052A (en) | 2014-10-09 | 2017-08-15 | Celgene Corp | TREATMENT OF CARDIOVASCULAR DISEASE USING ACTRII LIGAND TRAPS |
MD4801C1 (en) | 2014-12-03 | 2022-10-31 | Celgene Corporation | Activin-ActRII antagonists and uses for treating myelodysplastic syndromes |
CA2995310A1 (en) | 2015-08-25 | 2017-03-02 | Histide Ag | Compounds for inducing tissue formation and uses thereof |
ES2862103T3 (en) * | 2015-09-17 | 2021-10-07 | Histide Ag | Pharmaceutical associations of growth factor receptor agonists and adhesion protein inhibitors for the conversion of neoplastic cells into non-neoplastic cells and their uses |
PL3349778T3 (en) * | 2015-09-17 | 2021-12-27 | Histide Ag | Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof |
WO2023069447A1 (en) * | 2021-10-18 | 2023-04-27 | The Uab Research Foundation | Bmp9 or an agonist thereof and its uses related to reducing metastasis of cancer |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1435243A2 (en) * | 1998-11-13 | 2004-07-07 | Curis, Inc. | Methods of alleviating cancer symtoms |
US20060039949A1 (en) * | 2004-08-20 | 2006-02-23 | Nycz Jeffrey H | Acetabular cup with controlled release of an osteoinductive formulation |
WO2006029406A2 (en) * | 2004-09-09 | 2006-03-16 | Stryker Corporation | Methods for treating bone tumors using bone morphogenic proteins |
-
2006
- 2006-07-29 GB GBGB0615129.4A patent/GB0615129D0/en not_active Ceased
-
2007
- 2007-07-20 WO PCT/GB2007/002755 patent/WO2008015383A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1435243A2 (en) * | 1998-11-13 | 2004-07-07 | Curis, Inc. | Methods of alleviating cancer symtoms |
US20060039949A1 (en) * | 2004-08-20 | 2006-02-23 | Nycz Jeffrey H | Acetabular cup with controlled release of an osteoinductive formulation |
WO2006029406A2 (en) * | 2004-09-09 | 2006-03-16 | Stryker Corporation | Methods for treating bone tumors using bone morphogenic proteins |
Non-Patent Citations (3)
Title |
---|
DATABASE EMBL [online] 11 March 2004 (2004-03-11), ROSEN C.A. ET AL.: "New albumin fusion proteins useful for preparing a composition for treating diabetes mellitus", XP002474103, retrieved from WWW.EBI.AC.UK accession no. ADH22105 * |
SONG J.J. ET AL.: "Bone morphogentic protein-9 binds to liver cells and stimulates proliferation.", ENDOCRINOLOGY, vol. 136, no. 10, 1995, pages 4293 - 4297, XP002474102 * |
VARADY P. ET AL.: "Morphologic analysis of BMP-9 gene therapy induced osteogenesis.", HUMAN GENE THERAPY, vol. 12, 10 April 2001 (2001-04-10), pages 697 - 710, XP002474101 * |
Also Published As
Publication number | Publication date |
---|---|
GB0615129D0 (en) | 2006-09-06 |
WO2008015383A8 (en) | 2009-07-16 |
WO2008015383A2 (en) | 2008-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008015383A3 (en) | Bmp-9 and bmp-10 and their use in breast and prostate cancer therapies | |
WO2008076278A3 (en) | Methods of cancer treatment with igf1r inhibitors | |
HK1109638A1 (en) | Dr5 antibodies and uses thereof dr5 | |
IL195731A0 (en) | Pyrimidine derivatives useful in the treatment of cancer | |
MX2019015200A (en) | Diarylhydantoin compounds. | |
WO2006113483A3 (en) | Methods and compositions for treating or preventing cancer | |
EP2173740A4 (en) | Heme-oxygenase inhibitors and use of the same in the treatment of cancer and diseases of the central nervous system | |
WO2008089397A3 (en) | Adrb2 cancer markers | |
WO2009053041A3 (en) | Identification of tumor-associated markers for diagnosis and therapy | |
HK1170485A1 (en) | 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer 124--3- | |
WO2008150530A3 (en) | Cripto binding molecules | |
HUE037109T2 (en) | Endoxifen for use in the treatment of cancer | |
HK1215683A1 (en) | Antifolate agent combinations in the treatment of cancer | |
WO2008060945A3 (en) | Diagnosis and treatment of breast cancer | |
WO2007100920A3 (en) | Diagnosis and treatment of prostate cancer | |
MX2012001513A (en) | Use of melanocortins to treat dyslipidemia. | |
AU2006251169A8 (en) | Tetrahydropyridothiophenes for use in the treatment of cancer | |
AU2006251167A8 (en) | Tetrahydropyridothiophenes for use in the treatment of cancer | |
ZA200709542B (en) | Combination therapy in the treatment of cancer | |
WO2009074253A3 (en) | Clofarabine dietherphospholipid derivatives | |
WO2009046123A3 (en) | Nlrr-1 antagonists and uses thereof | |
WO2008009895A3 (en) | Matriptase-2 | |
WO2008092103A3 (en) | Combination cancer treatments comprising elsamitrucin and other agents | |
WO2008061048A3 (en) | Methods and compositions for diagnosing and treating prostate cancer | |
ZA200810524B (en) | Pyrimidine derivatives useful in the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07766318 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07766318 Country of ref document: EP Kind code of ref document: A2 |